all report title image

ONCOLOGY DRUGS MARKET ANALYSIS

Oncology Drugs Market, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Drug Type (Cytotoxic Drugs, Targeted Drugs), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, and Others), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Route of Administration (Oral and Parental), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

  • Published In : Mar 2024
  • Code : CMI2332
  • Pages :188
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Key Developments

  • On March 7, 2024, Bristol Myers Squibb, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.
  • On January 25, 2024, Alphamab Oncology, a clinical-stage biopharmaceutical company, and 3DMedicines, a leading innovative biopharmaceutical company, announced that they have entered into a license agreement with Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., a pharmaceutical company, for the subcutaneous injection PD-L1 antibody drug, pursuant to which Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology in India, Asia Pacific (except Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, CIS, and Latin America.
  • On January 12, 2024, Merck & Co., Inc., a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT), for the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer.
  • On January 8, 2024, Johnson & Johnson, a healthcare company, announced that it has signed a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company that uses a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs). Ambrx is advancing a focused portfolio of clinical and preclinical initiatives designed to maximize the efficacy and safety of its potential candidate in several cancer indications.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.